Ceralasertib is a Small Molecule owned by AstraZeneca, and is involved in 35 clinical trials, of which 7 were completed, 27 are ongoing, and 1 is planned.

Ceralasertib is a selective inhibitor of ATR serine/threonine protein kinase inhibitor (ataxia telangiectasia and rad3 related (ATR) kinase). AZD6738 selectively inhibits ATR activity by blocking the downstream phosphorylation of the serine/threonine protein kinase CHK1. This prevents ATR-mediated signaling and results in the inhibition of DNA damage checkpoint activation, disruption of DNA damage repair and the induction of tumor cell apoptosis.

The revenue for Ceralasertib is expected to reach a total of $335m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Ceralasertib NPV Report.

Ceralasertib is originated and owned by AstraZeneca.

Ceralasertib Overview

Ceralasertib is under development for the treatment of head and neck cancer squamous cell carcinoma, metastatic triple negative breast cancer, HER-2 negative breast cancer, non-small cell lung cancer, metastatic melanoma, advanced biliary tract cancer, endometrial cancer, cervical cancer, uterine cancer, small cell lung cancer, chronic myelomonocytic leukemia, metastatic hormone refractory (castration resistant, androgen-independent) prostate cancer, metastatic colorectal cancer, salivary gland cancer, myelodysplastic syndrome, homologous-recombination deficient (HRD) of adenocarcinoma of the gastroesophageal junction, non-hodgkin's lymphoma, ovarian cancer, peritoneal cancer, fallopian tube cancer, refractory solid tumors including lung adenocarcinoma, metastatic renal cell carcinoma, urothelial cell carcinoma, pancreatic ductal adenocarcinoma, other solid tumors. The drug candidate is administered through oral route in the form of film coated tablet and gelatin coated capsule. It targets ataxia telangiectasia and rad3 related (ATR) kinase.

It was also under development for the treatment of prolymphocytic leukemia (PLL), Burkitt lymphoma, acute lymphocytic leukemia, hairy cell leukemia (HCL), relapsed/refractory chronic lymphocytic leukemia (CLL), indolent  b-cell lymphoma and B cell lymphomas.

AstraZeneca Overview

AstraZeneca is a biopharmaceutical company, which is focused on discovery, production and commercialization of a range of prescription drugs. It develops products related to therapy areas such as respiratory, cardiovascular, renal and metabolic diseases, cancer, autoimmune, infection and neurological diseases. The company’s product portfolio includes biologics, prescription pharmaceuticals and vaccines. AstraZeneca sells its products through wholly-owned local marketing companies, distributors and local representative offices. The company markets its products to primary care and specialty care physicians. The COVID-19 Vaccine AstraZeneca has been approved for conditional marketing or emergency use. The company operates in Europe, the Americas, Asia, Africa and Australasia. AstraZeneca is headquartered in Cambridge, Cambridgeshire, the UK.

The company reported revenues of (US Dollars) US$37,417 million for the fiscal year ended December 2021 (FY2021), an increase of 40.6% over FY2020. In FY2021, the company’s operating margin was 2.8%, compared to an operating margin of 19.4% in FY2020. In FY2021, the company recorded a net margin of 0.3%, compared to a net margin of 12% in FY2020. The company reported revenues of US$10,982 million for the third quarter ended September 2022, an increase of 2% over the previous quarter.

Quick View – Ceralasertib

Report Segments
  • Innovator
Drug Name
  • Ceralasertib
Administration Pathway
  • Oral
Therapeutic Areas
  • Oncology
Key Companies
Highest Development Stage
  • Phase III

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.